1. Stem cell-based therapy has shown promise in treating a variety of tissue injury indications, but the therapeutic effect of BMSCs in bone regeneration is limited due to low cell viability and impaired differentiation capacity.
2. EVs are membrane-bound nanoparticles secreted by cells that contain proteins, nucleic acids, and lipids, and have been found to have comparable or superior efficacy and functional properties as direct stem cell transplantation with less adverse effects.
3. Hypoxia stimulation of MSCs can promote the secretion of various factors which can be enveloped in EVs, and an injectable bioactive hydrogel was developed to sustainedly deliver the fragile Hypo-EVs in vivo.
The article is overall trustworthy and reliable as it provides evidence for its claims through references to prior studies conducted on the topic. The article also presents both sides of the argument equally by discussing both the potential benefits of using EVs for bone regeneration as well as their associated risks such as immune rejection and tumor formation. Furthermore, possible risks are noted throughout the article such as low retention and poor stability of EVs in vivo which could compromise therapeutic effects.
However, there are some points that could be improved upon such as providing more evidence for certain claims made throughout the article or exploring counterarguments more thoroughly. Additionally, there is a lack of discussion regarding potential ethical considerations when using stem cells for therapy which should be addressed in future research on this topic.